

New Products - Perjeta

Perjeta (**pertuzumab**) is a recombinant humanised monoclonal antibody. Pertuzumab binds to the extracellular dimerisation domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and thereby blocks ligand-dependent heterodimerisation of HER2 with other HER family members, including EGFR, HER3 and HER4. It inhibits ligand initiated intracellular signalling through mitogen activated protein (MAP) kinase and phosphoinositide 3 kinase (PI3K). Inhibition can result in cell growth arrest and apoptosis, respectively. In addition, pertuzumab mediates antibody-dependent cell-mediated cytotoxicity (ADCC). Perjeta is indicated in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for their metastatic disease. Perjeta is available as a single dose vial containing 420 mg of pertuzumab (30 mg/mL).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.